TABLE 3.

An overview of the expression changes, roles, targets, mechanisms in ferroptosis, and therapeutic implications for various lncRNAs in lung cancer.

lncRNA	Expression change	Role	Target	Mechanism in ferroptosis	Therapeutic implications	Ref.
LINC00336	Upregulated	Inhibitor of ferroptosis	miR-6852, CBS	Acts as a ceRNA for miR-6852, regulating CBS expression via ELAVL1, impacting p53 signaling	Targeting LINC00336/MIR6852/CBS axis to induce ferroptosis in lung cancer	Pandey et al. (2024), Wang et al. (2019a), Wang et al. (2019b)
MIR503HG	Downregulated	Potential inhibitor	miR-1273c, SOX4	Sponges miR-1273c, regulating SOX4 expression, possibly affecting ferroptosis	XAV939 modulation in NSCLC may alter ferroptosis through lncRNA-miRNA-mRNA interactions	Yu et al. (2019)
H19	Downregulated	Inhibitor of ferroptosis	miR-19b-3p, FTH1	miR-19b-3p activity enhances, suppressing FTH1, triggering ferroptosis	Curcumenol targets H19/miR-19b-3p/FTH1 axis, potential lung cancer therapy	Zhang et al. (2022b)
GSEC	Upregulated in LUAD	Inhibitor of ferroptosis	miRNA-101-3p, CISD1	Regulates ferroptosis-related genes (CISD1), associated with poor prognosis	GSEC/miRNA-101-3p/CISD1 axis as prognostic marker and therapeutic target in LUAD	Jiang et al. (2021)
GMDS-AS1, LINC01128	-	Inhibitor of chemoresistance	miR-6077	Sponges miR-6077, overcoming chemoresistance in LUAD	Targeting miR-6077 to overcome chemoresistance	Bi et al. (2022)
HCP5	Upregulated	Inhibitor of brain metastasis	miR-17-5p, HOXA7	Competes with miR-17-5p, upregulating HOXA7, inhibiting brain metastasis	HCP5/hsa-miR-17-5p/HOXA7 axis in LUAD brain metastasis	Chen et al. (2022)
OGFRP1	Upregulated	Promoter of proliferation	miR-299-3p, SLC38A1	Regulates cell proliferation and ferroptosis through miR-299-3p and SLC38A1	Targeting OGFRP1/miR-299-3p/SLC38A1 axis for lung cancer treatment	Liu et al. (2022)
LINC00597	Upregulated	Promoter of ferroptosis	hsa-miR-367-3p, TFRC	Upregulates TFRC by sponging hsa-miR-367-3p, inducing ferroptosis	Cinobufotalin may offer novel therapeutic targets	Huang et al. (2023)
LINC00551	downregulated	Promoter of ferroptosis	miR-4328, DDIT4	Inhibits mTOR activity, promotes autophagy and ferroptosis in an autophagy-dependent manner	Potential therapeutic target in LUAD	Peng et al. (2022)
ITGB2-AS1	Upregulated	Promoter of chemoresistance	NAMPT, FOSL2, p53	Inhibits p53-mediated ferroptosis through NAMPT expression, binding to FOSL2	ITGB2-AS1 as a target to overcome cisplatin resistance in NSCLC	Chen et al. (2023)
SDCBP2-AS1	Upregulated	Inhibitor of ferroptosis	miR-656-3p, CRIM1	Sponges miR-656-3p, regulates CRIM1, promoting ferroptosis	Targeting SDCBP2-AS1/miR-656-3p/CRIM1 axis for lung cancer treatment	Dai et al. (2023)
NEAT1_1	Upregulated	Promoter of chemoresistance	miR-338-3p, AKR1C1	Promotes ferroptosis defense, leading to gefitinib resistance	Targeting NEAT1_1/miR-338-3p/AKR1C1 axis to overcome gefitinib resistance	Wu and Liu (2021), Zhen et al. (2024)
LUCAT1	Upregulated	Inhibitor of ferroptosis	GCH1, FSP1, miR-34a-5p	Downregulates GCH1 and FSP1, promoting ferroptosis through miR-34a-5p-mediated mechanisms	Inhibiting LUCAT1 to induce ferroptosis and inhibit lung cancer progression	Tai et al. (2024)
Uc.339	Upregulated	Inhibitor of ferroptosis	miR-339, SLC7A11	inds to pre-miR-339, inhibiting its maturation, and upregulates SLC7A11, suppressing ferroptosis	Targeting Uc.339 to promote ferroptosis and inhibit lung adenocarcinoma progression	Zhang et al. (2022a)